Date:5/15/2009

2 32,848,373 Total liabilities and stockholders' equity: $42,934,982 $36,758,921 Consolidated Statements of Operations and Comprehensive Income (Unaudited) For the Three Months Ended For the Nine Months Ended March 31, March 31, 2009 2008 2009 2008 Sales: $9,929,301 $9,249,229 $29,593,109 $24,167,921 Cost of sales: 5,069,133 5,123,587 14,696,736 13,984,845 Gross profit: 4,860,168 4,125,642 14,896,373 10,183,076 Operating expenses: Selling, general and administrative 2,481,188 2,180,161 7,709,861 4,380,702 Research and development 86,495 89,372 253,353 150,930 Total operating expenses: 2,567,683 2,269,533 7,963,214 4,531,632 Income from operations: 2,292,485 1,856,109 6,933,159 5,651,444 Other income (expenses): Other income 4,874 -- 34,682 -- Interest expense (20,821) (245,174) (75,515) (311,536) Total other income (expenses): (15,947) (245,174) (40,833) (311,536) Income before provision for income tax: 2,276,538 1,610,935 6,892,326 5,339,908 Provision for income tax: 380,521 337,132 1,148,197 893,779 Net income: 1,896,017 1,273,803 5,744,129 4,446,129 Other comprehensive income (loss): Foreign currency translation adjustment (50,359) 793,507 296,009 1,368,473 Comprehensive income: $1,845,658
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine news :

1. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
2. Tianyin Pharmaceutical to Present at Roth Third Annual China Discovery Tour in Beijing on May 20, 2008 at 12:40 p.m. Beijing Time
3. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2008 Third Quarter Earnings Conference Call on Thursday, May 15, 2008 at 9:00 a.m. EDT
4. Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results
5. Tianyin Pharmaceutical Signs Over 60 New Distribution Agreements with 15 Regional Distributors
6. Tianyin Pharmaceutical Co., Inc. Completes Production for Earthquake
7. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Simvastatin Tablets
8. Tianyin Pharmaceutical Co., Inc. Announces Trading Symbol Error and Correction
9. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets
10. Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program
11. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST